Avraham Pharmaceuticals

Prevention of Neurodegenerative Disorders

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
Avraham Pharmaceuticals
NeuroPharmacology | NeuroBioTechnology
Biotechnology & Biopharmaceutical
01/01/2010
"11-50"
Go to company site

Avraham Pharmaceuticals is an emerging pharmaceutical company developing novel products for the treatment and prevention of neurodegenerative disorders such as Alzheimer's disease, Lewy body disease, and Parkinson's disease.

The company's lead product candidate, Ladostigil, was exclusively in-licensed from the Hebrew University and the Technion and is in phase 2 clinical studies for mild cognitive impairment (MCI). Ladostigil is a multifunctional compound that combines neuro-protective mechanisms, reducing oxidative stress and microglial activation while inhibiting pro-inflammatory cytokines. Ladostigil may have the potential to slow the progression of Alzheimer's disease in patients diagnosed with MCI.